James Brockbank, MSc

Senior Director, Health Economics

Office Location

Telecommuter - UK

MSc, Health Economics and Decision Modelling
University of Sheffield, Sheffield, United Kingdom

BSc, Neuroscience
The University of Manchester, Manchester, United Kingdom

James Brockbank undertakes and manages projects dealing with health technology assessment submissions, cost-effectiveness and budget-impact modelling, country adaptations, development of conceptual models, systematic literature reviews, burden of illness, and micro-costing. Mr. Brockbank’s dissertation for graduate school focused on developing cost-effectiveness and budget-impact models for Alzheimer’s disease.

Send James Brockbank a message

Full Name

Business Title

Organization

Technical Area

Attachments

You may attach up to three PDF, Word or Excel documents.

Each document must be under 2 MB.

Maximum 3 files.
2 MB limit.
Allowed types: pdf doc docx xls xlsx txt.

Your message

Yes, I would like to receive updates on RTI-HS news, information, and events.

By submitting this form, you accept the RTI-HS privacy policy.

Selected Recent Publications

Brockbank J, Hancock H, Khare A, Joshi P, Risson V. Cost-effectiveness of [177Lu]Lu-PSMA-617 in progressive PSMA-positive metastatic castration-resistant prostate cancer. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S121. doi: 10.1016/j.jval.2024.10.619

Hancock H, Brockbank J, Brodtkorb TH, Lucherini S, Russell J. A review of cure assumptions implemented in early-stage oncology NICE appraisals. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S148. doi: 10.1016/j.jval.2022.09.714

Hancock H, Brockbank J, Theodorou E, Brodtkorb TH. Survival analysis methods used in immuno-oncology NICE appraisals. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S92. doi: 10.1016/j.jval.2022.09.451

Russell-Smith TA, Brockbank J, Mamolo C, Knight C. Cost effectiveness of gemtuzumab ozogamicin in the first-line treatment of acute myeloid leukaemia in the UK. Pharmacoecon Open. 2021 Dec;5(4):677-91. doi: 10.1007/s41669-021-00278-3

More Publications

James Brockbank, MSc

Senior Director, Health Economics

Send James Brockbank a message

How Can We Help You?